BioSimilar.
ValueDifferent.


BioSimilar.

ValueDifferent.

Similar.
But different.
Similar. But different.
UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences delivers the high-quality treatment and outcomes you expect, while reducing overall costs for your patients and your practice.1,2
It's time for another choice with UDENYCA®
Biosimilars are safe, effective, and affordable alternatives to existing brand biologics. At Coherus BioSciences, we’re committed to ensuring patient access to biologics through high-quality, high-value biosimilars.
Dosing &
administration


UDENYCA® is dosed and administered identically to Neulasta®.1

Comprehensive patient SUPPORT SERVICES
Coherus COMPLETE™ provides a suite of patient support services and programs
designed to assist with patient access.
Coherus COMPLETE™ provides a suite of patient support services and programs designed to assist with patient access.
References: 1. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019. 2. First Databank, Inc. Pricing Compendia.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.
- Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
- Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS.
- Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA® in patients with serious allergic reactions.
- Fatal sickle cell crises: Have occurred.
- Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely.
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS:
Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.
To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INDICATION
UDENYCA® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.